Company News
-
Time: 2024-12-10
KGX101, an Innovative IL-12 Prodrug by Kangabio, Completes First Patient Dosing in China -
Time: 2024-4-10
KangaBio present preclinical data of IL-12 prodrug KGX101 at AACR 2024 -
Time: 2023-12-13
KangaBio's IL-12 Prodrug KGX101: dosing of the first patient was completed -
Time: 2023-10-26
KangaBio's new generation IL-12 prodrug has been approved for IND application in the United States -
Time: 2021-08-01
Shanghai KangaBio Opening Ceremony -
Time: 2021-05-31
KangaBio and Immune Targeting Inc. sign a cooperation agreement
